Dataset Information


Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies.

ABSTRACT: We investigated the effect of the long-acting muscarinic antagonist aclidinium bromide on chronic obstructive pulmonary disease (COPD) exacerbations by pooling data from five randomized, placebo-controlled, parallel-group Phase III studies of 3-6 months' duration. Data were pooled from the aclidinium 400 ?g twice-daily (BID) and placebo arms (N  =  2,521) and stratified by Global initiative for chronic Obstructive Lung Disease (GOLD) group (A, B, C and D). Results showed that fewer patients experienced ?1 exacerbation with aclidinium (any severity: 12.5%; moderate to severe: 10.9%) compared with placebo (any severity: 15.7%; moderate to severe: 13.3%) and the odds of experiencing ?1 exacerbation of any severity were reduced in patients receiving aclidinium (odds ratio  =   0.78, p  =  0.039). Furthermore, aclidinium reduced the rate of exacerbations compared with placebo (any severity: rate ratio  =  0.79, p  =  0.026; moderate to severe: 0.80, p  =  0.044). The time to first exacerbation of any severity was delayed with aclidinium compared with placebo (hazard ratio  =  0.79, p  =  0.026) and there was a numerical delay in time to first moderate-to-severe exacerbation. Finally, the effects of aclidinium on exacerbations versus placebo were greater in patients in GOLD Groups B and D; however, it is of note that only 10.7% of patients were classified in Group A or C. In summary, the results indicate that aclidinium 400 ?g BID reduces the frequency of COPD exacerbations compared with placebo and that these effects are greater in symptomatic patients.


PROVIDER: S-EPMC5152596 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6396834 | BioStudies
2015-01-01 | S-EPMC4531806 | BioStudies
2019-01-01 | S-EPMC6506885 | BioStudies
2017-01-01 | S-EPMC5476673 | BioStudies
2016-01-01 | S-EPMC4877996 | BioStudies
2015-01-01 | S-EPMC5559124 | BioStudies
2017-01-01 | S-EPMC5450266 | BioStudies
1000-01-01 | S-EPMC5182036 | BioStudies
2011-01-01 | S-EPMC3098801 | BioStudies
1000-01-01 | S-EPMC5870740 | BioStudies